![](https://news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-144x144.jpg)
(IN BRIEF) Roche, a global pharmaceutical company, has shared compelling data from its CD20xCD3 T-cell engaging bispecific antibody program during the 65th American Society of Hematology (ASH) Annual Meeting & Exposition held in December 2023. The data includes extended follow-up … Read the full press release